The Technical Analyst
Trevena Inc [TRVN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Trevena Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.92% $0.392
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.94 mill |
| EPS: | -6.06 |
| P/E: | -0.0600 |
| Earnings Date: | Nov 06, 2023 |
| SharesOutstanding: | 15.17 mill |
| Avg Daily Volume: | 0.126 mill |
| RATING 2024-04-15 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0600 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.345 - 0.427 ( +/- 10.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-14 | Drake Patricia M. | Buy | 25 000 | Common Stock |
| 2023-12-14 | Drake Patricia M. | Sell | 1 835 | Common Stock |
| 2023-12-14 | Drake Patricia M. | Buy | 50 000 | Common Stock |
| 2023-12-14 | Bourdow Carrie L. | Buy | 100 000 | Common Stock |
| 2023-12-14 | Bourdow Carrie L. | Sell | 7 123 | Common Stock |
| INSIDER POWER |
|---|
| 92.79 |
| Last 98 transactions |
| Buy: 7 332 092 | Sell: 537 308 |
Forecast:
16:00 - $0.392
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.392
Forecast 2: 16:00 - $0.392
Forecast 3: 16:00 - $0.392
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.392 (2.92% ) |
| Volume | 0.0666 mill |
| Avg. Vol. | 0.126 mill |
| % of Avg. Vol | 52.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TRVN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 07:00:00 - Press Release
Trevena Reports Fourth Quarter 2023 Results And Provides Corporate Update
Trv045, novel s1p receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
2023-12-28 14:00:00 - Press Release
Trevena Announces The Closing Of $4 Million Concurrent Private Placement And Warrant Exercise
Chesterbrook, pa., dec. 28, 2023 (globe newswire) -- trevena, inc. (“trevena” or the “company”) (nasdaq: trvn), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (cns) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for gross proceeds to the company of approximately $1...
2023-12-27 09:10:00 - Press Release
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
Chesterbrook, pa., dec. 27, 2023 (globe newswire) -- trevena inc. (“trevena” or the “company”) (nasdaq: trvn), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (cns) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the company of approximately $1...
2023-12-04 07:02:00 - Press Release
Trevena Announces Trv045 Presentation At The American College Of Neuropsychopharmacology 62nd Annual Meeting
-- presentation highlighted promising results of trv045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
2023-12-04 07:00:00 - Press Release
Trevena Awarded Olinvyk Agreement With Premier, Inc.
Chesterbrook, pa., dec. 04, 2023 (globe newswire) -- trevena inc. (nasdaq: trvn), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (cns) disorders, has been awarded a national group purchasing agreement for olinvyk with premier, inc. effective december 1, 2023, the new agreement allows premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by premier for olinvyk.
Latest News
2023-06-05 09:10:15 - Zacks Investment Research
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
2023-05-31 11:16:41 - PennyStocks
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
2023-05-09 09:38:00 - Market Watch
‘It's ridiculous.' Buy short-term Treasury bills because debt-ceiling deal will come, says bond legend Bill Gross
Friday's bullish session on Wall Street seems to have gone nowhere, save for the Nasdaq Composite COMP wriggling its way out of a bear market.
2023-05-09 07:00:00 - GlobeNewsWire
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.
2023-05-09 06:34:00 - PennyStocks
Momentum Trading With Penny Stocks: Quick Guide
Use these tips to make money when momentum trading penny stocks The post Momentum Trading With Penny Stocks: Quick Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-05-08 13:31:00 - Market Watch
Trevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in China
Shares of Trevena Inc. TRVN exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares.
2023-05-08 10:34:40 - PennyStocks
Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data
2023-05-08 10:20:01 - InvestorPlace
Why Is Trevena (TRVN) Stock Up 165% Today?
Trevena (NASDAQ: TRVN ) stock is rocketing higher on Monday after Chinese partner Jiangsu Nhwa got approval for one of its treatments. The National Medical Products Administration granted approval to Jiangsu Nhwa for Trevena's OLINVYK.
2023-05-03 07:00:00 - GlobeNewsWire
Trevena to Participate in Three Upcoming Conferences
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences.
2023-03-31 15:07:10 - Seeking Alpha
Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript
Trevena, Inc. (NASDAQ:TRVN ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call.